Who Owns Bicara Therapeutics Stock?
NASDAQ: BCAXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 107.64%
- Institutions (% of float)
- 119.69%
- Held by insiders
- 10.07%
- Institutional holders
- 240
- Institutions 89.9%
- Insiders 10.1%
- Public and other 0.0%
Who owns Bicara Therapeutics stock?
Institutional investors own about 107.6% of Bicara Therapeutics's shares, spread across 240 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 10.07% of BCAX.
The largest institutional holders are RA Capital Management, L.P. (10.97%), T. Rowe Price Investment Management, Inc. (9.58%) and Siren, L.L.C. (8.47%). Together, the top 10 institutions control 66.4% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their BCAX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of BCAX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RA Capital Management, L.P. | 7.26M | 10.97% | 0.0% |
| T. Rowe Price Investment Management, Inc. | 6.34M | 9.58% | -4.0% |
| Siren, L.L.C. | 5.60M | 8.47% | -3.5% |
| Vestal Point Capital, LP | 5.25M | 7.93% | -3.2% |
| Deep Track Capital, Lp | 4.10M | 6.20% | +0.9% |
| Blackrock Inc. | 3.85M | 5.82% | +35.3% |
| Jupiter Topco LLC | 3.17M | 4.79% | +100.0% |
| Red Tree Management, LLC | 3.16M | 4.78% | -0.2% |
| TPG GP A, LLC | 3.01M | 4.55% | 0.0% |
| Vanguard Capital Management LLC | 2.22M | 3.35% | +24.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of BCAX
| Fund | Shares | % Held |
|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.18M | 3.29% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.68M | 2.53% |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 1.17M | 1.77% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.16M | 1.75% |
| iShares Trust-iShares Russell 2000 ETF | 1.13M | 1.71% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 1.00M | 1.52% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 944.90K | 1.43% |
| Franklin Strategic Series-FRANKLIN SMALL CAP GROWTH FUND | 623.69K | 0.94% |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 612.10K | 0.93% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 604.73K | 0.91% |
Frequently asked questions
Who is the largest shareholder of Bicara Therapeutics?
RA Capital Management, L.P. is the largest institutional shareholder of BCAX, owning 10.97% of shares outstanding (7.26M shares) as of its latest 13F filing.
What percentage of Bicara Therapeutics is owned by institutions?
Institutions own about 107.6% of BCAX shares and 119.7% of the public float.
How much of Bicara Therapeutics do insiders own?
Insiders, such as officers and directors, own about 10.07% of BCAX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.